Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine Specific Demethylase 1 (LSD1), also known as KDM1A, is a flavin-dependent amine oxidase that catalyzes the removal of methyl groups from mono-methylated and di-methylated lysines, specifically histone H3 at lysines K4 (H3K4me1/2) and K9 (H3K9me1/2). It plays a critical role in epigenetic regulation, influencing gene expression and various biological processes including development, hematopoiesis, and cell differentiation. LSD1 is also implicated in diseases such as cancer and cardiac remodeling, making it a potential therapeutic target.
Enzyme Inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine Specific Demethylase 1 (LSD1).